<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03168087</url>
  </required_header>
  <id_info>
    <org_study_id>B-1705/395-303</org_study_id>
    <nct_id>NCT03168087</nct_id>
  </id_info>
  <brief_title>Plasmalyte-148 Solution and Blood Coagulation</brief_title>
  <official_title>The Effect of a Plasmalyte-148 Solution on Blood Coagulation: In Vitro, Volunteer Study Using Rotational Thromboelastometry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Fluids administered intravenously may alter whole blood coagulation. However, little is known
      about the dose-response relationships of hemodilution in plasmalyte-148 solution.
      Investigators have therefore performed the present study to measure the effect of a
      plasmalyte-148 solution on the coagulation pathway according to the hemodilution level using
      a rotational thromboelastometry (ROTEMÂ®) tests.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 15, 2017</start_date>
  <completion_date type="Anticipated">September 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>FIBTEM</measure>
    <time_frame>During the rotational thromboelastometry analysis/ an average of 1 hour</time_frame>
    <description>Fibrinolytic pathway values of rotational thromboelastometry analysis/ FIBTEM is not an acronym.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>INTEM</measure>
    <time_frame>During the rotational thromboelastometry analysis/ an average of 1 hour</time_frame>
    <description>Intrinsic pathway values of rotational thromboelastometry analysis/ INTEM is not an acronym.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EMTEM</measure>
    <time_frame>During the rotational thromboelastometry analysis/ an average of 1 hour</time_frame>
    <description>Extrinsic pathway values of rotational thromboelastometry analysis/ EXTEM is not an acronym.</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Blood Coagulation Disorder</condition>
  <arm_group>
    <arm_group_label>0% dilution</arm_group_label>
    <description>Blood specimen which was diluted with 0% level using a plasmalyte-148 solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>20% dilution</arm_group_label>
    <description>Blood specimen which was diluted with 20% level using a plasmalyte-148 solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>40% dilution</arm_group_label>
    <description>Blood specimen which was diluted with 40% level using a plasmalyte-148 solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>60% dilution</arm_group_label>
    <description>Blood specimen which was diluted with 60% level using a plasmalyte-148 solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Plasmalyte-148</intervention_name>
    <description>Venous blood is taken from 12 healthy volunteers and divided into four specimen bottles, which were diluted with different levels (0%, 20%, 40%, and 60%) using a plasmalyte-148 solution.</description>
    <arm_group_label>20% dilution</arm_group_label>
    <arm_group_label>40% dilution</arm_group_label>
    <arm_group_label>60% dilution</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Healthy volunteers
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy volunteers

          -  Age: 20 to 65 years

          -  Body weight &gt; 50 kg

          -  Volunteers who provided informed consent

        Exclusion Criteria:

          -  Hematologic disease

          -  Anticoagulant medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyun-Jung Shin, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Bundang Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hyun-Jung Shin, PhD</last_name>
    <phone>+82-31-787-7508</phone>
    <email>medidoc@nate.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam-si</city>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyun-Jung Shin, Ph.D., M.D.</last_name>
      <phone>+82-10-8846-2023</phone>
      <email>medidoc@nate.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 24, 2017</study_first_submitted>
  <study_first_submitted_qc>May 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 30, 2017</study_first_posted>
  <last_update_submitted>April 16, 2018</last_update_submitted>
  <last_update_submitted_qc>April 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Bundang Hospital</investigator_affiliation>
    <investigator_full_name>Hyun-Jung Shin</investigator_full_name>
    <investigator_title>Assistant professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Blood Coagulation Disorders</mesh_term>
    <mesh_term>Hemostatic Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Plasma-lyte 148</mesh_term>
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

